Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6
ImmunityBio Inc Ordinary Shares -1.69% Pre
ImmunityBio Inc Ordinary Shares IBRX | 3.49 3.49 | -1.69% 0.00% Pre |
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:
IBRX) with a Neutral and raises the price target from $5 to $6.